This company offers a digital biopharmaceutical manufacturing platform that uses real-time data analysis and predictive control to optimize production. Their platform automates feedback systems and creates paperless processes, enabling more efficient and streamlined biomanufacturing.
Funding
Funding not disclosed
Founders
Product
Problem
Biopharmaceutical companies face challenges in scaling up production of complex biologics while maintaining quality, managing costs, and adhering to stringent regulatory requirements. Traditional biomanufacturing processes often lack real-time data integration and advanced control systems, leading to inefficiencies and potential inconsistencies in product quality.
Solution
Taiwan Bio-Manufacturing Corporation (TBMC) offers end-to-end contract development and manufacturing organization (CDMO) services, specializing in complex modalities such as mRNA drugs, viral vectors, cell therapies, and protein therapeutics. TBMC leverages a digital manufacturing platform that integrates inline data collection, intelligent analytics, and model predictive control to optimize biomanufacturing processes. Their Pharma 4.0 approach enables real-time monitoring, automated feedback control, and paperless operations across multiple plants. By combining advanced technologies with biomanufacturing expertise, TBMC aims to accelerate the development and production of high-quality biologics, supporting clients from research to commercial stages.
Target Audience
TBMC primarily serves biopharmaceutical companies seeking CDMO services for complex biologics, including those developing mRNA therapeutics, viral vectors, cell therapies, and protein drugs, from research and preclinical stages through clinical and commercial manufacturing.
Features
- End-to-end biomanufacturing services for nucleic acids, gene therapies, cell therapies, and protein drugs
- Digital Manufacturing Platform with inline data collection, data analysis & integration, and model predictive control
- Real-time monitoring system that seamlessly integrates upstream and downstream equipment with analytical instruments
- Automated equipment analysis and online process data analysis for real-time insights
- Cloud-based digital transmission of parameters for paperless operation and data flow between plants
- Proprietary CHO-C protein drug platform for rapid protein production and purification
- Viral vector platform supporting scalable gene and cell therapy manufacturing
- Comprehensive analytical capabilities with 80+ validated methods for product quality across modalities